Question 1

What is United States — Center for Drug Evaluation and Research?

Accepted Answer

United States — Center for Drug Evaluation and Research is a Entity.

Question 2

How often does United States — Center for Drug Evaluation and Research appear in global news?

Accepted Answer

Tracked across 7 news events drawn from 47 articles.

Question 3

When was United States — Center for Drug Evaluation and Research first tracked by Ergen?

Accepted Answer

First tracked on Jun 12, 2026.

Question 4

When was United States — Center for Drug Evaluation and Research last mentioned in news?

Accepted Answer

Last active on Aug 24, 2026.

Question 5

What is United States — Center for Drug Evaluation and Research's current news sentiment?

Accepted Answer

Aggregate sentiment score: 9 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is United States — Center for Drug Evaluation and Research in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 7 events.

Question 7

What is the most recent event involving United States — Center for Drug Evaluation and Research?

Accepted Answer

InnoCare Orelabrutinib Mesutoclax BTD China (Aug 03, 2026, 6 articles).

Question 8

How did the "InnoCare Orelabrutinib Mesutoclax BTD China" event impact United States — Center for Drug Evaluation and Research?

Accepted Answer

The CDE is the specific agency that granted the BTD, playing a key role in the regulatory process. Its decision is crucial for the accelerated development of the combination therapy.

Question 9

How did the "FDA Extends Capricor Deramiocel PDUFA Date" event impact United States — Center for Drug Evaluation and Research?

Accepted Answer

CBER accepted the amendment for review and classified it as major, necessitating the extended review period.

Question 10

How did the "Nicox NCX 470 China Regulatory Feedback" event impact United States — Center for Drug Evaluation and Research?

Accepted Answer

The United States — Center for Drug Evaluation and Research provided positive pre-submission regulatory feedback for NCX 470, which is crucial for the drug's approval process in China.

Question 11

How did the "FDA expands Casgevy approval to age 2" event impact United States — Center for Drug Evaluation and Research?

Accepted Answer

CBER, the FDA center responsible for the review, granted the supplemental approval and utilized expedited review programs.

Question 12

How did the "Akeso's gumokimab approved in China" event impact United States — Center for Drug Evaluation and Research?

Accepted Answer

The United States — Center for Drug Evaluation and Research accepted a supplemental New Drug Application for Gumokimab in active ankylosing spondylitis, indicating potential future market expansion for the drug.

Question 13

How did the "Kelun-Biotech SKB565 IND Approval" event impact United States — Center for Drug Evaluation and Research?

Accepted Answer

The CDE, as part of NMPA, approved the IND application, playing a regulatory role in the event.

Question 14

How did the "AstraZeneca licenses Zegfrovy from Dizal" event impact United States — Center for Drug Evaluation and Research?

Accepted Answer

China's CDE received sNDA for first-line Zegfrovy and granted Breakthrough Therapy Designation.

Question 15

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.